KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Table 4 Prognostic value of combined tumor/plasma KRAS status analyzed by PNA-PCR in a series of 242 metastatic colorectal cancer patients with matched samples

*KRAS status was categorized as: negative, mutation-negative tumor and matched plasma samples; discordant, discordant KRAS status in tumor and matched plasma samples; positive, mutation-positive tumor tissue and matched plasma samples.
CI, confidence interval; mo, month; OS, overall survival; PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.